Ketamine and Antidepressants: A Patient Comparison Checklist

Important: Compounded ketamine is not FDA-approved. FDA has not evaluated its safety, effectiveness, or quality before marketing. Ketamine injection is approved for anesthesia, not psychiatric conditions. Compounded ketamine nasal spray is different from FDA-approved Spravato (esketamine), and research on other formulations or treatment settings does not establish its benefits.

When reviewing a new depression treatment, a short checklist can help you move beyond claims about speed or success rates. Use these questions to compare the actual care plans offered to you.

1. What exactly is the treatment?

Write down the medication name, formulation, and route. SSRIs are one category of antidepressants; there are others. Ketamine injection, compounded ketamine nasal spray, and Spravato are distinct options with different approval status and evidence. Ask for an explanation if a description uses their names interchangeably.

2. What evidence fits my situation?

Ask whether the research involved people with your diagnosis and treatment history. Also ask whether it studied the same route and care setting. A result from an infusion study cannot establish what to expect from a compounded home spray.

3. How will we assess benefit?

Agree on specific goals and a reassessment date. Discuss both symptom measures and everyday functioning. A temporary altered sensation is not enough to establish sustained benefit, and a promise of improvement after one session should be viewed cautiously.

4. What risks and practical demands matter?

Ask about medication interactions, side effects, monitoring, follow-up, transportation if needed, costs, and what happens if you cannot continue. The NIMH medication overview describes important considerations for antidepressants. Risks need an individualized review rather than a simple mild-versus-severe ranking.

5. What happens if the plan changes?

Find out who will coordinate with your current clinician, what to do if symptoms worsen, and how medication changes will be managed. Do not stop an antidepressant or change a ketamine dose independently. A clear plan should include alternatives if benefit is absent or adverse effects outweigh improvement.

Spravato’s approved prescribing information includes specific safety and monitoring requirements. Those requirements are part of that product’s treatment approach; its approval cannot be used as evidence that a compounded spray is equivalent.

Bring the answers back to your priorities. Convenience, cost, and treatment preferences matter, but they should be weighed alongside evidence, risk, and access to appropriate care. There is no single comparison score that determines the right choice for everyone.

Safety and the treatment setting

Ketamine can cause sedation, dissociation, impaired thinking or coordination, nausea, increased blood pressure or heart rate, and slowed breathing. Abuse or misuse, worsening psychiatric symptoms, and urinary or bladder problems are also concerns. This is not a complete list of risks.

At home, a healthcare professional is not onsite to monitor you or respond immediately to an adverse reaction. Telehealth support does not provide the same monitoring as an onsite care team. Review these FDA ketamine risk alerts and discuss your health history, other medications, monitoring needs, and emergency plan with your clinician.

Discuss your options

Bliss Mist Rx LLC provides telehealth services; we do not manufacture or compound medication. If a clinician prescribes treatment, an independent, appropriately licensed compounding pharmacy dispenses it. A consultation does not guarantee a prescription or a particular outcome. Book a Free Virtual Appointment or Follow-Up to discuss questions about your care.

This article is general education and does not replace individualized medical advice.